Performance of PARI eFlow®

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 23, Issue 2, 2010, Pages 113-114

  Perkins, Walter ^a  

^a Transave Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ARIKACE; UNCLASSIFIED DRUG;

BRONCHIECTASIS; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; IN VITRO STUDY; INSTRUMENT STERILIZATION; LETTER; NEBULIZER;

AEROSOLS; AMIKACIN; ANTI-BACTERIAL AGENTS; DISINFECTION; EQUIPMENT DESIGN; HUMANS; LIPOSOMES; NEBULIZERS AND VAPORIZERS; TIME FACTORS;

EID: 77951125220     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2009.Cor1     Document Type: Letter

References (10)

1. Geller DE, Margaret Rosenfeld, David A. Waltz, Robert W. Wilmott, and the AeroDose TOBI Study Group: Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest. 2003;123:28-36.
2. Hubert D, et al.: Pharmacokineric comparison of inhaled tobramycin (TOBI) via PARI eFlow-rapid or PARI LC-Plus nebulizers in cystic fibrosis patients. Poster presentation at the ECFC conference in Belek, 2007. [Abstract in J Cyst Fibrosis. 6(Suppl. 1):S12. The full paper: Pharmacokinetics and safety of tobramycin administered by the PARI eFlow-rapid nebulizer in cystic fibrosis has recently been published in J Cyst Fibrosis. 2009;6:332-337.]
3. Mitchell JP, Nagel MW, Nichols S, and Nerbrink O: Laser diffractometry as a technique for rapid assessment of aerosol particle size from inhalers. J Aerosol Med. 2006;19:409-433.
4. Coates AL, Green M, Leung K, Louca E, Tservistas M, Chan J, Ribeiro N, Charron M: The challenges of quantitative measurement of lung depostion using 99Tc-DTPA from delivery systems with very different delivery times. J Aerosol Med 2007;20:320-329.
5. Coates AL, Green M, Leung K, Chan J, Ribeiro N, Louca E, Ratjen F, Charron M, Tservistas M, and Keller M: Rapid pulmonary delivery of inhaled tobramycin for pseudomonas infection in cystic fibrosis. Pediatr Pulmonol. 2008;43: 753-759.
6. Fischer R, et al.: Inhalation with the PARI eFlow rapid reduces treatment time burden significantly in adult CF patients without altering lung function. Poster presentation at the ECFC conference in Belek, 2008. [Abstract in J Cyst Fibrosis. 6(Suppl 1):S41.]
7. Militz S, et al.: E-Flow rapid: improved lung function and patient satisfaction with more volume delivered to the lungs during inhalation therapy in cystic fibrosis. Poster presented at the ECFC conference in Prague, 2008. [Abstract in J Cyst Fibrosis. 7(Suppl. 2):S67.]
8. Bakuridze L, Andrieu V, Dupond C, and Dubus JC: Does repeated disinfection of the e-Flow rapid-nebulizer affect in vitro performance? J Cystic Fibrosis. 2007;6:309-310.
9. Perkins WR, et al.: Aerosolization of liposomal amikacin (Arikace) using different nebulizers: selection of the eFlow-nebulizer. Poster presented at the NACF conference in Anaheim
10. 2007. [Abstract in Pediatric Pulmonology, 2007; 42(Suppl. 30):356.]